Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.

Antiviral therapy - 1 Jan 1999

Rubio A, Gómez-Cano M, Puig T, Leal M, Pérez-Olmeda M, Ruiz L, Clotet B, Rey C, Zamora L, Xaus N, Soriano V

Abstract excerpt

Patients harbouring drug-resistance viruses usually suffer a rise in serum viraemia after a variable period of time. We have investigated the relationship between the appearance of resistant genotypes and the viral load of each patient after treatment. Our objective was to assess the association between human immunodeficiency virus (HIV) RNA plasma levels and the number of drug resistance-associated point...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Didanosine

Share to Drug Resistance

Share to Genes, pol

Share to Lamivudine

Share to Zalcitabine

Share to Zidovudine

Source

Identifiers

PMID: 10682128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.PMID 10682128Read ↗

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.Semantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in SpainSemantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.Semantic proximity Read ↗

Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.Semantic proximity Read ↗

Prevalence of genotypic resistance in untreated HIV patients in Spain.Semantic proximity Read ↗

Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions.Semantic proximity Read ↗

Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens.Semantic proximity Read ↗

Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART.Semantic proximity Read ↗

Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.Semantic proximity Read ↗

Prevalence of genotypic resistance in untreated HIV-infected patients.Semantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy.Semantic proximity Read ↗

Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.